Literature DB >> 16574402

Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells.

Lian-Zhi Gu1, Wen-Yang Hu, Nenad Antic, Rajendra Mehta, Jerrold R Turner, Primal de Lanerolle.   

Abstract

We have previously shown that ML-7, which inhibits myosin light chain kinase (MLCK), induces apoptosis in transformed and non-transformed cells. We have extended these studies and found that ML-7 stimulates the ability of etoposide to induce apoptosis in Mm5MT mouse mammary adenocarcinoma cells and Mat-Ly-Lu rat prostate cancer cells in vitro. ML-7 was also found to have a chemopreventive effect using an in vitro mouse mammary organ culture model. In vivo experiments demonstrated that ML-7 retards the growth of mammary tumours in mice and prostate tumours in rats. Moreover, ML-7 significantly stimulates the ability of etoposide to prevent the growth of established mammary tumours in mice and prostate tumours in rats. These results provide evidence for the efficacy of ML-7 as an adjuvant to etoposide in these models and warrants further development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574402     DOI: 10.1016/j.ejca.2005.12.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway.

Authors:  Wen-jing Cui; Yi Liu; Xiao-lei Zhou; Feng-ze Wang; Xiao-dong Zhang; Li-hong Ye
Journal:  Acta Pharmacol Sin       Date:  2010-05-10       Impact factor: 6.150

2.  Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling.

Authors:  D Y Kim; D M Helfman
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

Review 3.  Targeting the cytoskeleton against metastatic dissemination.

Authors:  Carmen Ruggiero; Enzo Lalli
Journal:  Cancer Metastasis Rev       Date:  2021-01-20       Impact factor: 9.264

4.  Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells.

Authors:  Q Wu; R M Sahasrabudhe; L Z Luo; D W Lewis; S M Gollin; W S Saunders
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

5.  Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells.

Authors:  Quanwen Li; Raymond R Mattingly
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

6.  A novel tumor suppressor role of myosin light chain kinase splice variants through downregulation of the TEAD4/CD44 axis.

Authors:  Yen-Ju Huang; Tsung-Chun Lee; Yu-Chen Pai; Been-Ren Lin; Jerrold R Turner; Linda Chia-Hui Yu
Journal:  Carcinogenesis       Date:  2021-07-16       Impact factor: 4.944

7.  Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2.

Authors:  Yefei Rong; Dayong Jin; Chenrui Hou; Jianwen Hu; Wenchuan Wu; Xiaolin Ni; Dansong Wang; Wenhui Lou
Journal:  BMC Gastroenterol       Date:  2010-06-29       Impact factor: 3.067

8.  Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.

Authors:  André Fujita; Luciana Rodrigues Gomes; João Ricardo Sato; Rui Yamaguchi; Carlos Eduardo Thomaz; Mari Cleide Sogayar; Satoru Miyano
Journal:  BMC Syst Biol       Date:  2008-12-05

9.  Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.

Authors:  A Kondratskyi; M Yassine; C Slomianny; K Kondratska; D Gordienko; E Dewailly; V Lehen'kyi; R Skryma; N Prevarskaya
Journal:  Cell Death Dis       Date:  2014-04-24       Impact factor: 8.469

10.  Tumor stiffness is unrelated to myosin light chain phosphorylation in cancer cells.

Authors:  Hui-Jun Yu; Leonid A Serebryannyy; Madeline Fry; Madelyne Greene; Olga Chernaya; Wen-Yang Hu; Teng-Leong Chew; Nadim Mahmud; Shrihari S Kadkol; Sarah Glover; Gail Prins; Zuzana Strakova; Primal de Lanerolle
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.